Most Active Articles 2009-11-25T20:25:28.206-05:00 Business Exchange Business_Exchange@businessweek.com urn:com:businessweek:bx:topic:most-active:pharmaceutical-industry Ken Rhines krhines058 urn:com:businessweek:bx:article:8241957669382774010-aa05595011fcf5f84fe73103041d0ca1 2009-11-23T11:10:09.577-05:00

Nov. 23 (Bloomberg) -- Canadian doctors should hold off on using a batch of GlaxoSmithKline Plc’s swine flu vaccine temporarily while the company probes reports of higher-than- expected occurrences of a side effect known as anaphylaxis, a...

Nov. 23 (Bloomberg) -- Canadian doctors should hold off on using a batch of GlaxoSmithKline Plc’s swine flu vaccine temporarily while the company probes reports of higher-than- expected occurrences of a side effect known as anaphylaxis, a... http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aVGjbiOcdiIw Leslie MacCallum lmaccallum946 2 2 0 0 urn:com:businessweek:bx:article:16451597115752087574-d819eca6c9d952760b3c9f0ef25b7b60 2009-11-19T06:23:54.835-05:00

The law of nature shows a dependence of various species of living beings on each other which is primarily a survival phenomenon of the larger animal "eating" away the smaller one for survival thus completing the "food chain". Ever heard of a lizard...

The law of nature shows a dependence of various species of living beings on each other which is primarily a survival phenomenon of the larger animal "eating" away the smaller one for survival thus completing the "food chain". Ever heard of a lizard... http://blogs.veedacr.com/Lists/Categories/Category.aspx?Name=Outsourcing%20Clinical%20Research Rashmi Pant rpant537 5 4 1 0 urn:com:businessweek:bx:article:10474804778506115800-9026ed673bfda0f0ca1675c9418de481 2009-11-18T15:31:00.480-05:00

Marvelle Sullivan, the head of corporate legal M&A at Novartis AG (NYSE:NVS), spoke at The Deal Economy 2010 conference on Wednesday in New York City. In this video, she explains several challenges confronting companies working on cross-border...

Marvelle Sullivan, the head of corporate legal M&A at Novartis AG (NYSE:NVS), spoke at The Deal Economy 2010 conference on Wednesday in New York City. In this video, she explains several challenges confronting companies working on cross-border... http://www.thedeal.com/dealscape/2009/11/novartis_sullivan_on.php Brennen Wysong bwysong598 3 3 0 0 urn:com:businessweek:bx:article:4341155033288484302-1067bff79cf7a94ebff245a39c3a8378 2009-10-29T06:01:05.861-04:00

World leaders meet at the illustrious NGP Summit in Florida to face up to economic woes.

World leaders meet at the illustrious NGP Summit in Florida to face up to economic woes. http://www.ngonlinenews.com/news/big-pharma-back-MandA/ Sophie Crossman scrossman043 34 33 1 0 urn:com:businessweek:bx:article:5487041416984347101-c930006e50417497a7af477c0647f86f 2009-11-11T02:36:19.817-05:00

http://www.the-scientist.com/blog/display/56142/

http://www.the-scientist.com/blog/display/56142/ http://www.the-scientist.com/blog/display/56142/ Rashmi Pant rpant537 6 5 0 1 urn:com:businessweek:bx:article:14925009496694729302-8d042eea6f09e0af5e7ccff72a33714b 2009-11-10T14:44:25.358-05:00

Pfizer Inc. (NYSE:PFE) employees concerned about their jobs may have a better idea of where they stand. The pharmaceutical giant on Monday announced plans to consolidate 20 R&D centers into five central hubs as part of its integration of Wyeth.

Pfizer Inc. (NYSE:PFE) employees concerned about their jobs may have a better idea of where they stand. The pharmaceutical giant on Monday announced plans to consolidate 20 R&D centers into five central hubs as part of its integration of Wyeth. http://www.thedeal.com/corporatedealmaker/2009/11/pfizer_slashing_rd_footprint_b.php Brennen Wysong bwysong598 10 10 0 0 urn:com:businessweek:bx:article:9906666587082922265-00eaeb34eb167e31a0f61972b70514d0 2009-11-04T22:21:35.819-05:00

Nov. 4 (Bloomberg) -- Merck KGaA of Germany is gambling an unproven therapy that spurs the immune system to attack cancer cells will increase its share of a $48 billion oncology market. Merck is enrolling more than 900 women globally in an...

Nov. 4 (Bloomberg) -- Merck KGaA of Germany is gambling an unproven therapy that spurs the immune system to attack cancer cells will increase its share of a $48 billion oncology market. Merck is enrolling more than 900 women globally in an... http://www.bloomberg.com/apps/news?pid=20601085&sid=aD2rO8iba81U Rashmi Pant rpant537 12 12 0 0 urn:com:businessweek:bx:article:13580349519666135866-29f9a2084e8e6ed001ba7f898419b5b8 2009-11-04T14:53:44.050-05:00

Two weeks after Johnson & Johnson (NYSE:JNJ) reported mixed earnings, which tugged stocks downward, the world's biggest healthcare company is looking to cut costs. Those cuts include 7,000 to 8,000 layoffs, mostly overseas.

Two weeks after Johnson & Johnson (NYSE:JNJ) reported mixed earnings, which tugged stocks downward, the world's biggest healthcare company is looking to cut costs. Those cuts include 7,000 to 8,000 layoffs, mostly overseas. http://www.thedeal.com/corporatedealmaker/2009/11/jj_chief_calls_job_cuts_diffic.php Brennen Wysong bwysong598 16 16 0 0 urn:com:businessweek:bx:article:16812423169456113629-128dd389d0ee647c54f65527e0e518f6 2009-11-06T16:00:31.978-05:00

The approval by U.S. antitrust regulators of Pfizer Inc.'s (NYSE:PFE) acquisition of Wyeth is an outlier of how merger reviews will be conducted under the Obama administration. That's according to Jeffrey Schmidt, a partner with Linklaters and a former director of the Federal Trade Commission's office of competition under President George W. Bush. Schmidt, who will be discussing the antitrust landscape at The Deal Economy 2010 conference Nov. 18 and 19, says based on reports about the review, it seems regulators expanded their investigation beyond what would have taken place un

The approval by U.S. antitrust regulators of Pfizer Inc.'s (NYSE:PFE) acquisition of Wyeth is an outlier of how merger reviews will be conducted under the Obama administration. That's according to Jeffrey Schmidt, a partner with Linklaters and a former director of the Federal Trade Commission's office of competition under President George W. Bush. Schmidt, who will be discussing the antitrust landscape at The Deal Economy 2010 conference Nov. 18 and 19, says based on reports about the review, it seems regulators expanded their investigation beyond what would have taken place un http://www.thedeal.com/corporatedealmaker/2009/11/linklaters_schmidt_on_pfizer-w.php Brennen Wysong bwysong598 8 8 0 0 urn:com:businessweek:bx:article:3146372830617165237-e776fc7430d37dea205cd6a2fe3dac9e 2009-11-10T07:12:11.646-05:00

Placebos are getting more "effective". It sounds absurd but many "clinical studies "in the world of clinical research have proved so. This explains the success and failure of new drugs in the clinical trials during the process of drug development.

Placebos are getting more "effective". It sounds absurd but many "clinical studies "in the world of clinical research have proved so. This explains the success and failure of new drugs in the clinical trials during the process of drug development. http://blogs.veedacr.com/Lists/Categories/Category.aspx?Name=New%20Drug%20Development%20%28NCE%29 Rashmi Pant rpant537 4 4 0 0 urn:com:businessweek:bx:article:8589270569295086659-b50d38c6ddedd852767155200e5179e8 2009-11-01T16:12:26.446-05:00

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- In a speech today to the City Club of San Diego, John C. Lechleiter, Ph.D., chairman and chief executive officer of Eli Lilly and Company (NYSE: LLY), said that the engine of biopharmaceutical innovation...

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- In a speech today to the City Club of San Diego, John C. Lechleiter, Ph.D., chairman and chief executive officer of Eli Lilly and Company (NYSE: LLY), said that the engine of biopharmaceutical innovation... http://www.benzinga.com/press-releases/n33309/lilly-ceo-lechleiter-calls-for-repair-of-the-engine-of-biopharma-innovation-sp Michael Arndt marndt561 7 7 0 0 urn:com:businessweek:bx:article:15959165569034481739-5efcc23c1464770bb3d4170519830da1 2009-10-29T17:05:14.254-04:00

Sept. 25 (Bloomberg) -- GlaxoSmithKline Plc’s search outside its own laboratories for new drugs is getting more difficult because of increased competition from rivals “desperate” for novel treatments, according to the company’s head of research and...

Sept. 25 (Bloomberg) -- GlaxoSmithKline Plc’s search outside its own laboratories for new drugs is getting more difficult because of increased competition from rivals “desperate” for novel treatments, according to the company’s head of research and... http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aUb73rPBTkaE Robin Yong ryong995 11 10 0 1 urn:com:businessweek:bx:article:14838256404163446072-7f23a6dd1d45ec4602e46acd6a9d96ad 2009-11-10T07:11:09.029-05:00

The Indian generic market has been plagued with reports of Indian counterfeit medicines getting sold in important African Markets.

The Indian generic market has been plagued with reports of Indian counterfeit medicines getting sold in important African Markets. http://blogs.veedacr.com/Lists/Categories/Category.aspx?Name=Generics Rashmi Pant rpant537 2 2 0 0 urn:com:businessweek:bx:article:6164801333215536596-1a345c6f0ea428e2cca4fbb80b51afd8 2009-11-10T07:15:33.091-05:00

A "2" way approach to business The Cancer Health forecasts are very promising and are expected to grow at a rate which is higher than the world pharma market growth rate. The market is expected to reach a an approximate size of greater than US $ 75...

A "2" way approach to business The Cancer Health forecasts are very promising and are expected to grow at a rate which is higher than the world pharma market growth rate. The market is expected to reach a an approximate size of greater than US $ 75... http://blogs.veedacr.com/Lists/Categories/Category.aspx?Name=Cancer Rashmi Pant rpant537 1 1 0 0 urn:com:businessweek:bx:article:10005356048803928350-44ba1a4108dde878b65256317dd00d96 2009-11-05T13:22:18.066-05:00

The H1N1 virus has now become the dominant influenza virus around the globe, with high levels and an increase of activity in many regions, the World Health Organization said Thursday.

The H1N1 virus has now become the dominant influenza virus around the globe, with high levels and an increase of activity in many regions, the World Health Organization said Thursday. http://www.cnn.com/2009/HEALTH/11/05/h1n1.flu.who.global/ Shirley Brady sbrady224 6 6 0 0 urn:com:businessweek:bx:article:15784453230940966286-8f76fbe7e8981f18a9d5b85da605b41b 2009-10-20T04:40:00.909-04:00

Once a powerful profit-machine, big pharma is stumbling ,the threat of further government intervention, drying product pipelines, fierce competition from generic manufacturers, consumer concerns about safety, and false marketing claims is forcing leaders to revisit operations to secure top line Growth. So leaders such as Judith Marquis, Group VP Genzyme, Jeffrey Nye, Chief Medical Officer J&J Pharmaceuticals and James Kirwin VP Global Clinical Operation Wyeth Pharmaceuticals are uniting with over 50 other figureheads at the renowned NGP US Summit next week in Florida to discuss future technology investments to strengthen the industry and improve efficiency to “weather the Healthcare Reform”.

Once a powerful profit-machine, big pharma is stumbling ,the threat of further government intervention, drying product pipelines, fierce competition from generic manufacturers, consumer concerns about safety, and false marketing claims is forcing leaders to revisit operations to secure top line Growth. So leaders such as Judith Marquis, Group VP Genzyme, Jeffrey Nye, Chief Medical Officer J&J Pharmaceuticals and James Kirwin VP Global Clinical Operation Wyeth Pharmaceuticals are uniting with over 50 other figureheads at the renowned NGP US Summit next week in Florida to discuss future technology investments to strengthen the industry and improve efficiency to “weather the Healthcare Reform”. http://current.com/items/91228334_pharmaceutical-industry-set-to-emerge-as-winners-in-the-healthcare-reform.htm Emma Naylor enaylor109 20 20 0 0 urn:com:businessweek:bx:article:2941391682959073148-6373e2c42629bcf16b0a6a89a5d56b57 2009-11-02T14:06:36.218-05:00

My, how far CME has come in the age of technology! It seems like just yesterday that CME was in the infancy stage of being offered through websites and portals. But now with the advent of ReachMD and its unique XM Radio/iPhone/social media approach...

My, how far CME has come in the age of technology! It seems like just yesterday that CME was in the infancy stage of being offered through websites and portals. But now with the advent of ReachMD and its unique XM Radio/iPhone/social media approach... http://srcomblog.wordpress.com/2009/11/02/300-reasons-cme-is-evolving/ Ayubu Azizi aazizi497 4 4 0 0 urn:com:businessweek:bx:article:7905358182006758655-bed411c8b72f56cb36bb890c8b7c8969 2009-11-02T15:51:32.040-05:00

When Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) bought Proteolix Inc. on Oct. 12, (The Deal Pipeline subscription required) it was the first-ever acquisition for the 17-year-old Emeryville, Calif. firm. And in an industry underpinned by licensing deals, Onyx has only signed two, both coming in 2008. Rather than look outside for growth, Onyx has been developing Nexavar, a drug approved in more than 100 countries to treat liver and kidney cancers.

When Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) bought Proteolix Inc. on Oct. 12, (The Deal Pipeline subscription required) it was the first-ever acquisition for the 17-year-old Emeryville, Calif. firm. And in an industry underpinned by licensing deals, Onyx has only signed two, both coming in 2008. Rather than look outside for growth, Onyx has been developing Nexavar, a drug approved in more than 100 countries to treat liver and kidney cancers. http://www.thedeal.com/corporatedealmaker/2009/11/onyx_pharma_dealmakers_on_buil.php Brennen Wysong bwysong598 6 6 0 0 urn:com:businessweek:bx:article:17923857497913327171-e78582292c1c1d1dc711d47a9216e3a6 2009-10-28T01:57:31.438-04:00

An explicit indicator of the government intervention in the Corporate strategies of Indian companies is a headliner in todays' key newspapers and also featuring in the news is an opinion from the Glenmark CEO. The published news has featured...

An explicit indicator of the government intervention in the Corporate strategies of Indian companies is a headliner in todays' key newspapers and also featuring in the news is an opinion from the Glenmark CEO. The published news has featured... http://blogs.veedacr.com/Lists/Categories/Category.aspx?Name=Indian%20Pharma Rashmi Pant rpant537 3 3 0 0 urn:com:businessweek:bx:article:10436027000213254198-dda0f82c655b11b48a36ba9ef4d22e7d 2009-10-20T10:44:26.028-04:00

78 percent of US interested in mobile healthcare solutions

78 percent of US interested in mobile healthcare solutions http://srcomblog.wordpress.com/2009/10/19/78-percent-of-us-interested-in-mobile-healthcare-solutions/ Ayubu Azizi aazizi497 7 7 0 0 urn:com:businessweek:bx:article:1732957641349726033-3b5f9fae87220628390b0fb475792c0b 2009-10-20T13:29:39.260-04:00

SAN FRANCISCO, Calif., Oct. 20 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, announced today that Frederick L. Hall, President and CEO, and Dr. Erlinda M. Gordon, Medical...

SAN FRANCISCO, Calif., Oct. 20 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, announced today that Frederick L. Hall, President and CEO, and Dr. Erlinda M. Gordon, Medical... http://www.send2press.com/newswire/2009-10-1020-003.shtml Christopher Simmons csimmons281 2 1 1 0 urn:com:businessweek:bx:article:17602940323366025863-37b42be41b6000dc35427de3bdc3c064 2009-10-05T04:55:00.000-04:00

I am in the process of developing LogiPharma 2010, a conference for supply chain and logistics decision makers in the pharmaceutical industry, taking...

I am in the process of developing LogiPharma 2010, a conference for supply chain and logistics decision makers in the pharmaceutical industry, taking... http://www.linkedin.com/answers/management/organizational-development/MGM_ODV/560422-8298416 14 14 0 0 urn:com:businessweek:bx:article:17157515297585969303-72464f7b2c401aecc823de2407e21169 2009-10-16T14:53:26.107-04:00

On Wednesday, Pfizer Inc. (NYSE:PFE) received approval from the FTC for its $68 billion acquisition of Wyeth. Friday is Day One for the combined companies. The mood at the two giant organizations no doubt varies by function and location. But a juxtaposition of two facts in a Bloomberg report suggests the swirl of emotions researchers at the two companies may be feeling.

On Wednesday, Pfizer Inc. (NYSE:PFE) received approval from the FTC for its $68 billion acquisition of Wyeth. Friday is Day One for the combined companies. The mood at the two giant organizations no doubt varies by function and location. But a juxtaposition of two facts in a Bloomberg report suggests the swirl of emotions researchers at the two companies may be feeling. http://www.thedeal.com/corporatedealmaker/2009/10/pfizer-wyeth_day_one.php Brennen Wysong bwysong598 6 6 0 0 urn:com:businessweek:bx:article:15597421068609565522-bac7c4b79e26517493837078551d7506 2009-10-12T03:34:55.773-04:00

The race to offer H1N1 flu vaccination is picking up pace. While global H1N1 vaccine manufacturers like Sanofi Pasteur, Novartis and MedImmune have begun shipping their products, Indian vaccine majors Serum Institute of India, Panacea Biotech and Bharat Biotech are likely to start human clinical trials by the year-end and the H1N1 vaccine will hit the market by March-April next year.

The race to offer H1N1 flu vaccination is picking up pace. While global H1N1 vaccine manufacturers like Sanofi Pasteur, Novartis and MedImmune have begun shipping their products, Indian vaccine majors Serum Institute of India, Panacea Biotech and Bharat Biotech are likely to start human clinical trials by the year-end and the H1N1 vaccine will hit the market by March-April next year. http://www.financialexpress.com/news/vaccines-are-hot/527770/ Bruce Einhorn beinhorn468 3 3 0 0 urn:com:businessweek:bx:article:15749541781070750834-8fd887a88279392ef4acc9ab3416d676 2009-09-29T13:48:15.812-04:00

Amid rising flu concerns, three big drug companies have formed deals that give them rights to new vaccines.

Amid rising flu concerns, three big drug companies have formed deals that give them rights to new vaccines. http://online.wsj.com/article/SB125417905531847679.html?mod=WSJ_hpp_LEFTTopStories Arlene Weintraub aweintraub678 5 5 0 0